Literature DB >> 17633789

Lapatinib.

Beverly Moy, Peter Kirkpatrick, Santwana Kar, Paul Goss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17633789     DOI： 10.1038/nrd2332

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  46 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

2.  Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Authors:  Julian R Molina; Scott H Kaufmann; Joel M Reid; Stephen D Rubin; Marina Gálvez-Peralta; Robert Friedman; Karen S Flatten; Kevin M Koch; Tona M Gilmer; Robert J Mullin; Roxanne C Jewell; Sara J Felten; Sumithra Mandrekar; Alex A Adjei; Charles Erlichman
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 3.  Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications.

Authors:  Hui-Wen Lo
Journal:  Discov Med       Date:  2010-07       Impact factor: 2.970

Review 4.  Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

Authors:  Woody Han; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

5.  EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.

Authors:  Jennifer L Woodring; Gautam Patel; Jessey Erath; Ranjan Behera; Patricia J Lee; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  Medchemcomm       Date:  2015-02       Impact factor: 3.597

6.  From bench to bedside: the growing use of translational research in cancer medicine.

Authors:  Erin M Goldblatt; Wen-Hwa Lee
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

7.  Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.

Authors:  Joanna K Towles; Rebecca N Clark; Michelle D Wahlin; Vinita Uttamsingh; Allan E Rettie; Klarissa D Jackson
Journal:  Drug Metab Dispos       Date:  2016-07-22       Impact factor: 3.922

8.  Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.

Authors:  Klarissa D Hardy; Michelle D Wahlin; Ioannis Papageorgiou; Jashvant D Unadkat; Allan E Rettie; Sidney D Nelson
Journal:  Drug Metab Dispos       Date:  2013-11-04       Impact factor: 3.922

Review 9.  Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selection.

Authors:  Melanie Spears; John M S Bartlett
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

10.  The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Authors:  Kaushal Asrani; Ruth A Keri; Rebeca Galisteo; Sharron A N Brown; Sarah J Morgan; Arundhati Ghosh; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2013-02-01       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.